Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320870 | 1.00 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL3314735 | 0.85 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL13396431 | 0.85 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL24686959 | 0.83 | ADK (0.51) | ADORA1LMNAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL16378775 | 0.82 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL29444514 | 0.82 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL31526248 | 0.82 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL22402681 | 0.82 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL22601403 | 0.82 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL30827092 | 0.82 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | PI4KA 267/4885PI4K2B 740/4885PI4K2A 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.